Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.
Soria A, Fava M, Bernasconi DP, Lapadula G, Colella E, Valsecchi MG, Migliorino GM, D'Ambrosio R, Landonio S, Schiavini M, Spinetti A, Carriero C, Degasperi E, Cologni G, Gatti F, Viganò P, Hasson H, Uberti-Foppa C, Pasulo L, Baiguera C, Rossotti R, Vinci M, Puoti M, Giorgini A, Menzaghi B, Lombardi A, Pan A, Aghemo A, Grossi PA, Boldizzoni R, Colombo S, Viganò M, Rumi MG, Del Poggio P, Valenti L, Giglio O, De Bona A, d'Arminio Monforte A, Colombo A, Spinelli O, Pigozzi MG, Molteni C, Bonfanti P, Terreni N, Perini P, Capretti A, Bella D, Liani C, Polo S, Aimo G, Pagnucco L, Bhoori S, Centenaro R, Graffeo M, Ciaccio A, Dionigi E, Lazzaroni S, Carderi I, Di Marco M, Rizzardini G, Noventa F, Lampertico P, Fagiuoli S. Soria A, et al. Among authors: giorgini a. Liver Int. 2020 Apr;40(4):769-777. doi: 10.1111/liv.14386. Epub 2020 Feb 3. Liver Int. 2020. PMID: 31970845
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C.
D'Ambrosio R, Pasulo L, Puoti M, Vinci M, Schiavini M, Lazzaroni S, Soria A, Gatti F, Menzaghi B, Aghemo A, Capelli F, Rumi MG, Morini L, Giorgini A, Pigozzi MG, Rossini A, Maggiolo F, Pan A, Memoli M, Spinelli O, Del Poggio P, Saladino V, Spinetti A, De Bona A, Capretti A, Uberti-Foppa C, Bonfanti P, Terreni N, Menozzi F, Colombo AE, Giglio O, Centenaro R, Borghi M, Baiguera C, Picciotto V, Landonio S, Gori A, Magnani C, Noventa F, Paolucci S, Lampertico P, Fagiuoli S; NAVIGATORE-Lombardia Study Group. D'Ambrosio R, et al. Among authors: giorgini a. J Hepatol. 2019 Mar;70(3):379-387. doi: 10.1016/j.jhep.2018.11.011. Epub 2018 Nov 23. J Hepatol. 2019. PMID: 30472321
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
Degasperi E, Spinetti A, Lombardi A, Landonio S, Rossi MC, Pasulo L, Pozzoni P, Giorgini A, Fabris P, Romano A, Lomonaco L, Puoti M, Vinci M, Gatti F, Carolo G, Zoncada A, Bonfanti P, Russo FP, Aghemo A, Soria A, Centenaro R, Maggiolo F, Rovere P, Pasin F, Paon V, Faggiano G, Vario A, Grossi G, Soffredini R, Carriero C, Paolucci S, Noventa F, Alberti A, Lampertico P, Fagiuoli S; NAVIGATORE-Lombardia and Veneto Study Groups. Degasperi E, et al. Among authors: giorgini a. J Hepatol. 2019 Dec;71(6):1106-1115. doi: 10.1016/j.jhep.2019.07.020. Epub 2019 Aug 6. J Hepatol. 2019. PMID: 31433303
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study.
D'Ambrosio R, Pasulo L, Giorgini A, Spinetti A, Messina E, Fanetti I, Puoti M, Aghemo A, Viganò P, Vinci M, Menzaghi B, Lombardi A, Pan A, Pigozzi MG, Grossi P, Lazzaroni S, Spinelli O, Invernizzi P, Maggiolo F, Terreni N, Monforte AD, Poggio PD, Taddei MT, Colombo S, Pozzoni P, Molteni C, Brocchieri A, Bhoori S, Buscarini E, Centenaro R, Mendeni M, Colombo AE, Di Marco M, Dionigi E, Bella D, Borghi M, Zuin M, Zaltron S, Noventa F, Annalisa S, Lampertico P, Fagiuoli S. D'Ambrosio R, et al. Among authors: giorgini a. Dig Liver Dis. 2020 Feb;52(2):190-198. doi: 10.1016/j.dld.2019.11.006. Epub 2019 Dec 6. Dig Liver Dis. 2020. PMID: 31813755
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting.
Fabbiani M, Lombardi A, Colaneri M, Del Poggio P, Perini P, D'Ambrosio R, Degasperi E, Dibenedetto C, Giorgini A, Pasulo L, Maggiolo F, Castelli F, Brambilla P, Spinelli O, Re T, Lleo A, Rumi M, Uberti-Foppa C, Soria A, Aghemo A, Lampertico P, Baiguera C, Schiavini M, Fagiuoli S, Bruno R; NAVIGATORE-Lombardia Study Group. Fabbiani M, et al. Among authors: giorgini a. J Viral Hepat. 2021 Mar;28(3):558-568. doi: 10.1111/jvh.13454. Epub 2021 Jan 2. J Viral Hepat. 2021. PMID: 33306247
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort.
Quaranta MG, Ferrigno L, Tata X, D'Angelo F, Massari M, Coppola C, Biliotti E, Giorgini A, Laccabue D, Ciancio A, Blanc PL, Margotti M, Ieluzzi D, Brunetto MR, Barbaro F, Russo FP, Beretta I, Morsica G, Verucchi G, Saracino A, Galli M, Kondili LA; PITER Collaborating Group. Quaranta MG, et al. Among authors: giorgini a. Dig Liver Dis. 2021 Dec;53(12):1603-1609. doi: 10.1016/j.dld.2021.03.020. Epub 2021 Apr 21. Dig Liver Dis. 2021. PMID: 33893040 Free article.
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study.
Valenti L, Pelusi S, Aghemo A, Gritti S, Pasulo L, Bianco C, Iegri C, Cologni G, Degasperi E, D'Ambrosio R, Del Poggio P, Soria A, Puoti M, Carderi I, Pigozzi MG, Carriero C, Spinetti A, Zuccaro V, Memoli M, Giorgini A, Viganò M, Rumi MG, Re T, Spinelli O, Colombo MC, Quirino T, Menzaghi B, Lorini G, Pan A, D'Arminio Monforte A, Buscarini E, Autolitano A, Bonfanti P, Terreni N, Aimo G, Mendeni M, Prati D, Lampertico P, Colombo M, Fagiuoli S; NAVIGATORE-Lombardia Network. Valenti L, et al. Among authors: giorgini a. Hepatol Commun. 2022 Apr;6(4):867-877. doi: 10.1002/hep4.1851. Epub 2021 Nov 22. Hepatol Commun. 2022. PMID: 34811949 Free PMC article.
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team. Petta S, et al. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10. Lancet Gastroenterol Hepatol. 2017. PMID: 28497758
Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study.
Aghemo A, Alberti A, Andreone P, Angelico M, Brunetto MR, Chessa L, Ciancio A, Craxì A, Gaeta GB, Galli M, Gasbarrini A, Giorgini A, Grilli E, Lampertico P, Lichtner M, Milella M, Morisco F, Persico M, Pirisi M, Puoti M, Raimondo G, Romano A, Russello M, Sangiovanni V, Schiavini M, Serviddio G, Villa E, Vinci M, De Michina A, Gallinaro V, Gualberti G, Roscini AS, Zignego AL; MARS Study Group. Aghemo A, et al. Among authors: giorgini a. Dig Liver Dis. 2021 May;53(5):612-619. doi: 10.1016/j.dld.2020.08.007. Epub 2020 Sep 8. Dig Liver Dis. 2021. PMID: 32917546
112 results